AcuTect sales add to Diatide results

Article

In its first quarterly statement since it began selling its AcuTect acute venous thrombosis agent, radiopharmaceutical firm Diatide last month reported fiscal and fourth-quarter (end-December) 1998 results. The Londonderry, NH, company’s year-end

In its first quarterly statement since it began selling its AcuTect acute venous thrombosis agent, radiopharmaceutical firm Diatide last month reported fiscal and fourth-quarter (end-December) 1998 results. The Londonderry, NH, company’s year-end revenues were $6.4 million, compared with $4.1 million in 1997. The company’s net loss for the year was $10.2 million, compared with $11 million the year before.

Diatide’s annual revenues for both 1997 and 1998 were primarily due to milestone payments from sales and marketing partner Nycomed Amersham. Nycomed paid Diatide $4 million in 1998, when it filed a new drug application for NeoTect, a lung cancer imaging agent, and when it received Food and Drug Administration clearance for AcuTect (SCAN 10/14/98). Diatide’s 1997 revenues included a $2 million milestone payment from Nycomed for Diatide’s NDA for AcuTect.

Diatide’s fourth-quarter revenues were $717,000, up from $510,000 the year before. Its net loss for the fourth quarter was $3.4 million, compared with $3.8 million in 1997. AcuTect contributed $177,000 to Diatide’s fourth-quarter revenues, a number that company executives acknowledged was disappointing. The firm attributed the slow start to the complexity of its marketing effort: In October AcuTect was introduced to physicians who make diagnoses, and in January it was presented to referring physicians.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.